| Title |
Bitter Melon: Antagonist to Cancer
|
|---|---|
| Published in |
Pharmaceutical Research, March 2010
|
| DOI | 10.1007/s11095-010-0057-2 |
| Pubmed ID | |
| Authors |
Pratibha Nerurkar, Ratna B. Ray |
| Abstract |
The incidence of cancer is increasing worldwide, in spite of substantial progress in the development of anti-cancer therapies. One approach to control cancer could be its prevention by diet, which inhibits one or more neoplastic events and reduces cancer risk. Dietary compounds offer great potential in the fight against cancer by inhibiting the carcinogenesis process through the regulation of cell homeostasis and cell-death machineries. For centuries, Ayurveda (Indian traditional medicine) has recommended the use of bitter melon (Momordica charantia) as a functional food to prevent and treat diabetes and associated complications. It is noteworthy to mention that bitter melon extract has no-to-low side effects in animals as well as in humans. The anti-tumor activity of bitter melon has recently begun to emerge. This review focuses on recent advancements in cancer chemopreventive and anti-cancer efficacy of bitter melon and its active constituents. Several groups of investigators have reported that treatment of bitter-melon-related products in a number of cancer cell lines induces cell cycle arrest and apoptosis without affecting normal cell growth. Therefore, the effect of bitter melon should be beneficial for health, and use of the non-modified dietary product is cost effective. |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 1% |
| United States | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 96 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 23 | 23% |
| Researcher | 12 | 12% |
| Student > Master | 10 | 10% |
| Student > Ph. D. Student | 9 | 9% |
| Student > Postgraduate | 5 | 5% |
| Other | 17 | 17% |
| Unknown | 23 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 24 | 24% |
| Medicine and Dentistry | 13 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 9% |
| Biochemistry, Genetics and Molecular Biology | 6 | 6% |
| Chemistry | 5 | 5% |
| Other | 17 | 17% |
| Unknown | 25 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2014.
All research outputs
#20,242,779
of 22,770,070 outputs
Outputs from Pharmaceutical Research
#2,641
of 2,855 outputs
Outputs of similar age
#89,239
of 93,480 outputs
Outputs of similar age from Pharmaceutical Research
#51
of 51 outputs
Altmetric has tracked 22,770,070 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,855 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 93,480 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.